Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Lixte Biotechnology Holdings Inc    LIXT

LIXTE BIOTECHNOLOGY HOLDINGS INC (LIXT)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 07:36:48 pm
0.95 USD   +5.56%
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2018 | 12:11pm CET

Item 3.02 Unregistered Sales of Equity Securities

Effective as of November 30, 2018, pursuant to a rights offering to its existing stockholders, the Company sold 9,000,000 units to 15 accredited investors for aggregate proceeds of $4,500,000. Each Unit consisted of one share of Common Stock (a "Share") and a four year warrant (a "Warrant") to purchase a share of Common Stock at $1.00 per share. The proceeds from the sale of the Units will be used for working capital and general corporate purposes principally in connection with the Company's ongoing clinical trials.

The Shares and Warrants issued to the investors were not registered under the Securities Act of 1933, as amended (the "Act"), in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act. Such securities may not be re-offered or sold in the United States in the absence of a registration statement or exemption from the registration requirements of the Act.

Item 9.01 Financial Statements and Exhibits



(d) Exhibits


There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIXTE BIOTECHNOLOGY HOLDIN
12/06LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Unregistered Sale of Equity Securities, Fin..
AQ
11/08LIXTE BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/07LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Other Events, Financial Statements and Exhi..
AQ
11/06LIXTE BIOTECHNOLOGY : FDA Approves Lixte Biotechnologys IND to Conduct a Phase 1..
AQ
11/05LIXTE BIOTECHNOLOGY : FDA Approves Lixte Biotechnology's IND to Conduct a Phase ..
AQ
10/10LIXTE BIOTECHNOLOGY : Files an IND with the FDA to Conduct a Phase 1b/2 Trial of..
AQ
10/09Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial o..
GL
08/23LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Entry into a Material Definitive Agreement,..
AQ
08/21Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer ..
GL
08/09LIXTE BIOTECHNOLOGY HOLDINGS, INC. : Change in Directors or Principal Officers, ..
AQ
More news
Chart LIXTE BIOTECHNOLOGY HOLDINGS INC
Duration : Period :
Lixte Biotechnology Holdings Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
John S. Kovach President, CEO, CFO, Director & CAO
Philip F. Palmedo Independent Director
Stephen J. Forman Director
Yun Yen Director
Winson Ho Director
Sector and Competitors
1st jan.Capitalization (M$)
LIXTE BIOTECHNOLOGY HOLDINGS INC475.76%0
IQVIA HOLDINGS INC20.55%23 609
CELLTRION, INC.--.--%23 068
LONZA GROUP14.51%22 493
INCYTE CORPORATION-30.05%14 099
SEATTLE GENETICS, INC.13.05%9 759